Avitia Unveils AI-Powered Platform for Fast, Point-of-Care Cancer Testing
Avitia, an AI company providing end-to-end testing solutions to rapidly identify cancer mutations and applicable treatments, has officially launched its business with a $5M seed investment from PacBridge Capital Partners (“PacBridge”). Avitia’s innovative platform enables laboratories and clinicians worldwide to conduct advanced molecular testing on-site, offering rapid, cost-effective cancer diagnostics without relying on centralized facilities. This breakthrough allows healthcare teams to quickly access critical cancer insights and initiate treatment faster, significantly improving patient outcomes.
Expansion and Adoption
With its new funding, Avitia plans to expand into new markets and further enhance its AI-driven platform. Currently, the company’s technology is utilized by partners across Canada, the United States, and Southeast Asia. Over 40,000 life-saving cancer mutation tests have already been conducted using Avitia’s platform, reinforcing its role as a trusted innovator in global cancer care.
Commitment to Accessibility
“Avitia believes that all patients deserve access to advanced, cost-effective testing, regardless of geographic or economic constraints,” said James Lumsdaine, CEO of Avitia and Partner at PacBridge. “We are building on technology initially developed by Imagia Canexia Health, incorporating AI innovations from Mila, the Quebec Artificial Intelligence Institute, to expand access to cutting-edge cancer diagnostics worldwide.”
Addressing Oncology’s Pressing Challenges
One of the most significant challenges in oncology is providing timely genomic testing that delivers actionable insights for oncologists. Studies from the American Society of Clinical Oncology (ASCO) highlight how travel distance can be a major barrier to accessing quality cancer care, directly impacting patient outcomes. Avitia’s modular technology addresses this issue by enabling local cancer centers to conduct next-generation sequencing (NGS) tests on-site, significantly reducing turnaround times and costs compared to centralized labs.
By integrating AI-driven bioinformatics tailored to regional and patient-specific needs, Avitia empowers oncologists with the tools needed to accelerate personalized cancer treatment. The company’s data-driven approach removes logistical hurdles, ensuring that patients receive precise, timely care.
Clinical Validation
Avitia’s technology has already demonstrated its potential to revolutionize cancer diagnostics.
“Using minimally invasive liquid biopsy technology, Avitia has proven effective in improving patient monitoring and treatment response, particularly for aggressive endometrial and ovarian cancers,” said Dr. Jessica McAlpine, an oncologist at the University of British Columbia and British Columbia Cancer Agency. “Our recent retrospective study found that Avitia’s liquid biopsy platform detected disease recurrence months before conventional clinical, radiologic, and biomarker methods.”
Montréal: A Hub for AI and Life Sciences
Avitia’s presence in Montréal strengthens the city’s reputation as a global leader in artificial intelligence and life sciences.
“Greater Montréal is renowned for its expertise in AI and healthcare innovation. Avitia’s project supports the retention of highly qualified talent while deploying locally developed, lifesaving technology,” said Stéphane Paquet, President and CEO of Montréal International.
The company has also partnered with Mila, a leading AI research institute, to ensure that its AI algorithms meet the highest standards of accuracy and reliability.
“As AI plays an increasingly vital role in healthcare, ensuring its accuracy is critical,” said Stéphane Létourneau, Executive Vice-President of Mila. “We welcome as a Mila partner and look forward to contributing to their advancements in AI-powered cancer diagnostics.”
About Avitia
delivers cutting-edge NGS-molecular testing solutions through its AI-driven platform, allowing laboratories to conduct advanced molecular diagnostics with ease. The company’s modular precision medicine technology provides cancer centers with state-of-the-art NGS capabilities, empowering local oncologists with real-time, actionable data. By bringing molecular testing closer to patients, enhances accessibility, speeds up diagnosis, and reduces costs, ultimately improving patient outcomes worldwide.
For more information, visit: www.avitia.bio
About PacBridge Capital Partners
PacBridge Capital Partners (HK) Limited is a Hong Kong-based investment firm specializing in growth-stage investments. Established in 2009, the firm works closely with portfolio companies to enhance business performance through strategic investments and operational expertise. Several PacBridge-backed companies have successfully gone public on major stock exchanges, including the Stock Exchange of Hong Kong and Nasdaq.
About Montréal International
Montréal International is a non-profit organization dedicated to attracting and retaining foreign investment, international organizations, and top-tier talent in Greater Montréal. The organization collaborates with private sector partners and government entities to strengthen the city’s economic ecosystem and position it as a leader in AI and life sciences.
